Covid-19 in Ocrelizumab-treated people with Multiple Sclerosis

This article, written by the Journal of Multiple Sclerosis and related disorders,  (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum. The objective was to better understand the SARS-CoV-2 infection in ocrelizumab-treated people with MS. The results show: Roche/Genentech clinical trial data: There were 51 (1.3%) […]

Time matters.

Know the signs. Change the story.

Every experience of MS is different. Early recognition, diagnosis, treatment and support can make a meaningful difference.

Visit our MS Awareness Week hub to hear real stories, learn more about MS,
and discover ways to get involved.